(Q44603657)

4 December 2017

title

Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD (English)

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00844-8

16 March 2024

author name string

Shih-Hua Lin

1

1 reference

4 December 2017

Yuh-Feng Lin

2

1 reference

4 December 2017

Shi-Wen Kuo

3

1 reference

4 December 2017

Yu-Juei Hsu

4

1 reference

4 December 2017

Yi-Jen Hung

5

1 reference

4 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14520628

16 March 2024

publication date

1 October 2003

1 reference

full work available at URL

4 December 2017

https://api.elsevier.com/content/article/PII:S0272638603008448?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00844-8

https://api.elsevier.com/content/article/PII:S0272638603008448?httpAccept=text/plain

16 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00844-8

American Journal of Kidney Diseases

16 March 2024

published in

1 reference

4 December 2017

volume

42

1 reference

4 December 2017

issue

4

1 reference

4 December 2017

page(s)

774-780

1 reference

Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Insulin resistance in uremia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Acute metabolic effects of dialysis fluids during CAPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Nonhypoglycemic effects of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Metabolic and additional vascular effects of thiazolidinediones.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

HOMA index to assess insulin resistance in renal failure patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Insulin resistance in uremia: effect of dialysis modality.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Resistin, obesity, and insulin resistance--the emerging role of the adipocyte as an endocrine organ

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

A family of tissue-specific resistin-like molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Troglitazone induces GLUT4 translocation in L6 myotubes.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Pharmacokinetics of rosiglitazone in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900844-8

7 January 2021

Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output

23

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(03)00844-8

16 March 2024

Identifiers

1 reference

4 December 2017

1 reference